388 related articles for article (PubMed ID: 15475801)
1. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
3. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
4. [Cisplatin ototoxicity. A clinical study].
Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
[TBL] [Abstract][Full Text] [Related]
5. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig.
Ekborn A; Lindberg A; Laurell G; Wallin I; Eksborg S; Ehrsson H
Cancer Chemother Pharmacol; 2003 Jan; 51(1):36-42. PubMed ID: 12497204
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
8. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
9. High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study.
Buzaid AC; Murren J; Durivage HJ
Am J Clin Oncol; 1991 Jun; 14(3):203-7. PubMed ID: 1851602
[TBL] [Abstract][Full Text] [Related]
10. AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity.
Cooper LB; Chan DK; Roediger FC; Shaffer BR; Fraser JF; Musatov S; Selesnick SH; Kaplitt MG
Otol Neurotol; 2006 Jun; 27(4):484-90. PubMed ID: 16791039
[TBL] [Abstract][Full Text] [Related]
11. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
[TBL] [Abstract][Full Text] [Related]
12. [Ototoxicity of cisplatin in children with malignant diseases].
Hadjilaskari P; Fengler R; Hartmann R; Henze G
Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
[TBL] [Abstract][Full Text] [Related]
13. [Hearing loss caused by high dose carboplatin therapy].
Lautermann J; Adamczyk M; ten Cate WJ; Kloke O
Laryngorhinootologie; 1998 Feb; 77(2):82-4. PubMed ID: 9555700
[TBL] [Abstract][Full Text] [Related]
14. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-induced hearing loss does not correlate with intracellular platinum concentration.
Ramírez-Camacho R; Fernández DE; Verdaguer JM; Gómez MM; Trinidad A; García-Berrocal JR; Corvillo MA
Acta Otolaryngol; 2008 May; 128(5):505-9. PubMed ID: 18421602
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
18. High-dose cisplatin treatment: hearing loss and plasma concentrations.
Laurell G; Jungnelius U
Laryngoscope; 1990 Jul; 100(7):724-34. PubMed ID: 2362532
[TBL] [Abstract][Full Text] [Related]
19. The incidence of hearing impairment after successful treatment of neuroblastoma.
Simon T; Hero B; Dupuis W; Selle B; Berthold F
Klin Padiatr; 2002; 214(4):149-52. PubMed ID: 12165893
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of cisplatin ototoxicity and progress in otoprotection.
Rybak LP
Curr Opin Otolaryngol Head Neck Surg; 2007 Oct; 15(5):364-9. PubMed ID: 17823555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
